Search research articles
Contact Us
Filters
Showing results (151-160 of 176) with videos related to
Page
of 18
Sort By:
The Journal of Biological Chemistry
|
April 22, 2022
Antibody recognition of complement factor H reveals a flexible loop involved in atypical hemolytic uremic syndrome pathogenesis
Takanori Yokoo, Aki Tanabe, Yoko Yoshida, et al.
Clinical and Experimental Nephrology
|
July 10, 2015
Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan
Naoko Ito, Hiroshi Hataya, Ken Saida, et al.
Clinical and Experimental Nephrology
|
July 25, 2018
Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance
Shuichi Ito, Yoshihiko Hidaka, Norimitsu Inoue, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
February 2, 2012
ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score
Hiroaki Takaya, Masahito Uemura, Yoshihiro Fujimura, et al.
International Journal of Hematology
|
August 20, 2014
Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation
Takeshi Matsumoto, Xinping Fan, Eiji Ishikawa, et al.
Blood
|
September 16, 2017
Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura
Marie Scully, Paul Knöbl, Karim Kentouche, et al.
Journal of Thrombosis and Haemostasis : JTH
|
January 12, 2021
Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura
Kazuya Sakai, Yoshihiro Fujimura, Yasuyuki Nagata, et al.
Alcoholism, Clinical and Experimental Research
|
December 31, 2005
Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis
Masahito Uemura, Tomomi Matsuyama, Masatoshi Ishikawa, et al.
Thrombosis and Haemostasis
|
August 5, 2009
Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis
Naoko Watanabe, Hitoshi Ikeda, Yukio Kume, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie
|
June 26, 2025
Irradiation with 265-nm Ultraviolet Light-Emitting Diodes to Plasma: Alterations of Hemostatic Parameters and von Willebrand Factor
Tomoya Hayashi, Yoshihiro Fujimura, Yoshihiko Sakurai, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 176) with videos related to
Sort By:
Page
of 18
The Journal of Biological Chemistry
|
April 22, 2022
Antibody recognition of complement factor H reveals a flexible loop involved in atypical hemolytic uremic syndrome pathogenesis
Takanori Yokoo, Aki Tanabe, Yoko Yoshida, et al.
Clinical and Experimental Nephrology
|
July 10, 2015
Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan
Naoko Ito, Hiroshi Hataya, Ken Saida, et al.
Clinical and Experimental Nephrology
|
July 25, 2018
Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance
Shuichi Ito, Yoshihiko Hidaka, Norimitsu Inoue, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
February 2, 2012
ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score
Hiroaki Takaya, Masahito Uemura, Yoshihiro Fujimura, et al.
International Journal of Hematology
|
August 20, 2014
Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation
Takeshi Matsumoto, Xinping Fan, Eiji Ishikawa, et al.
Blood
|
September 16, 2017
Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura
Marie Scully, Paul Knöbl, Karim Kentouche, et al.
Journal of Thrombosis and Haemostasis : JTH
|
January 12, 2021
Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura
Kazuya Sakai, Yoshihiro Fujimura, Yasuyuki Nagata, et al.
Alcoholism, Clinical and Experimental Research
|
December 31, 2005
Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis
Masahito Uemura, Tomomi Matsuyama, Masatoshi Ishikawa, et al.
Thrombosis and Haemostasis
|
August 5, 2009
Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis
Naoko Watanabe, Hitoshi Ikeda, Yukio Kume, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie
|
June 26, 2025
Irradiation with 265-nm Ultraviolet Light-Emitting Diodes to Plasma: Alterations of Hemostatic Parameters and von Willebrand Factor
Tomoya Hayashi, Yoshihiro Fujimura, Yoshihiko Sakurai, et al.
Page
of 18